[{"id":"88bb823f-8d19-42f2-88d3-d87f1401dab8","acronym":"BALLI-01","url":"https://clinicaltrials.gov/study/NCT04150497","created_at":"2021-01-18T20:14:43.892Z","updated_at":"2024-07-02T16:35:35.864Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","source_id_and_acronym":"NCT04150497 - BALLI-01","lead_sponsor":"Cellectis S.A.","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • lasmecabtagene timgedleucel (UCART22)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/14/2019","start_date":" 10/14/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-09-25"}]